Biotech Values

[DewDiligence]

The MYL webcast was actually not the same song and dance with respect to Copaxone. By being non-responsive to the question asked and responding instead to the question of clinical significance (#msg-95940059), MYL’s executives were (perhaps unbeknownst to themselves) implicitly acknowledging that their Copaxone product is different from branded Copaxone. If it were the same, the executives on the webcast would simply have said so instead of diverting the conversation to clinical significance.

This episode was similar to the scene one often sees in police movies and TV shows: A detective asks the suspect if he killed the victim and, instead of giving a simple denial, the suspect says, “Why would I do that?”

Bottom line: As a MNTA shareholder, I now feel slightly more confident that MNTA will get Copaxone approval before MYL.